Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

AstraZeneca, Merck & Co.'s PARP inhibitor Lynparza gains EU approval in breast cancer

firstwordpharmaApril 10, 2019

Tag: AstraZeneca , Merck & Co.'s PARP , Lynparza

PharmaSources Customer Service